乌鲁木齐地区78例HCV感染者基因型及亚型的临床研究
|
摘要
目的:探讨丙型肝炎病毒(HCV)基因型及亚型在乌鲁木齐地区的分布特点及流行优势株、基因型在年龄、民族、性别、丙型肝炎感染途径、肝病严重程度、HCV RNA载量、ALT水平的意义等方面进行观察和分析以探讨HCV基因分型的意义,为临床制定治疗方案和判断预后提供参考依据。方法:在82份抗HCV抗体和HCV RNA均阳性的血清标本中,分别提取HCV RNA,通过PCR-反向点杂交法进行基因分型检测。同时收集病人的一般资料、感染途径、肝功能等资料进行登记。应用SPSS 17 for windows软件,进行统计分析,计量资料应用t检验,计数资料应用χ2检验。结果:1. 82例抗HCV抗体和HCV RNA阳性标本中,有78例可进行基因分型,其中1(1b)型47例占60.26%,2(2a)型16例占20.51%,3型(3a8例,3b 5例)占16.67%,6(6a)型2例占2.56%。2.≤50岁和>50岁基因型总体分布差异经χ2检验有统计学意义(χ2=13.183,P=0.004<0.05)。3. HCV基因型维、汉两民族中的分布差异经χ2检验没有统计学意义(χ2=0.729,P=0.866>0.05)。4. HCV基因型在女性、男性间的分布差异经χ2检验没有统计学意义(χ2=4.422,P=0.219>0.05)。5.经χ2检验,在HCV感染的不同肝病程度患者的基因型分布有统计学意义(χ2=23.052,P=0.001<0.05)。6.经χ2检验,HCV基因型与感染途径有显著性差异(χ2=60.270,P=0.000<0.05)。7.通过不同基因型之间ALT、HCV RNA载量对比分析,经单因素方差分析,基因型之间ALT水平有显著差异(F=4.539,P=0.014<0.05)。经单因素方差分析,基因型之间HCV RNA载量无显著差异(F=2.059,P=0.135>0.05)。结论:乌鲁木齐地区流行的HCV基因型为1(1b),2(2a),3(3a、3b),6(6a)4型,1型为流行的主要基因型,2,3,6型均占相当比例,初步说明乌鲁木齐地区HCV流行的基因型呈现多样性。
Objective: To study the distribution of HCV genotypes and subtypes in Urumqi area and to know the relationship between HCV genotype and age, nationality, sex, hepatitis C transmission, severity of hepatopathy, serum load of HCV RNA and level of ALT. Methods: HCV RNA extracted from the Serum specimens of 82 patients with anti-HCV and HCV RNA positive was amplified by PCR, and then test the genotype of HCV RNA by using reverse dot-blot. At the same time, the general data of the patients, the transmission approach, liver functions were registered.We applicated SPSS 17 for windows to statistic analysis, t test for measurement data andχ2 test for numeration data. Results: 1. 82 Serum specimens from HCV infected patients were examined.78 Serum specimens can be genotyped for HCV RNA. In 78 Serum specimens, 60.26%(47/78), 20.51%(16/78), 16.67%(13/78) and 2.56%(2/78) belong to genotype 1(1b), genotype 2(2a), genotype 3(3a、3b) and genotype 6(6a). 2. The different on the distribution of HCV genotypes was significant between≤50years old and >50years old(χ2=13.183,P=0.004<0.05). 3. There had no significant difference between the Han nationality and the Uygur nationality(χ2=0.729, P=0.866>0.05). 4 .The difference was not statistically significant between female and male(χ2=4.422, P=0.219>0.05). 5.χ2 test, The distributions of genotype in different level of hepatopathy with HCV infected was statistically significant(χ2=23.052, P=0.001<0.05).6. Analyze relation between HCV genotype and route of infection. The distributions of genotype had significant difference(χ2=60.270 , P=0.000<0.05). 7. Contrastively analyze ALT level and quantitation of HCV RNA in different genotypes, through one-factor analysis of variance, there was significant different of ALT levels in different genotypes(F=4.539, P=0.014<0.05).There was not significant different of quantitation of HCV RNA in different genotypes(F=2.059, P=0.135>0.05). Conclusions: The HCV genotypes found in Urumqi area are 1, 2, 3, and 6. HCV genotype 1 is the main genotype, and genotypes 2, 3, and 6 accounts for some proportions, that interpret the diversity of HCV genotype in Urumqi.
Objective: To study the distribution of HCV genotypes and subtypes in Urumqi area and to know the relationship between HCV genotype and age, nationality, sex, hepatitis C transmission, severity of hepatopathy, serum load of HCV RNA and level of ALT. Methods: HCV RNA extracted from the Serum specimens of 82 patients with anti-HCV and HCV RNA positive was amplified by PCR, and then test the genotype of HCV RNA by using reverse dot-blot. At the same time, the general data of the patients, the transmission approach, liver functions were registered.We applicated SPSS 17 for windows to statistic analysis, t test for measurement data andχ2 test for numeration data. Results: 1. 82 Serum specimens from HCV infected patients were examined.78 Serum specimens can be genotyped for HCV RNA. In 78 Serum specimens, 60.26%(47/78), 20.51%(16/78), 16.67%(13/78) and 2.56%(2/78) belong to genotype 1(1b), genotype 2(2a), genotype 3(3a、3b) and genotype 6(6a). 2. The different on the distribution of HCV genotypes was significant between≤50years old and >50years old(χ2=13.183,P=0.004<0.05). 3. There had no significant difference between the Han nationality and the Uygur nationality(χ2=0.729, P=0.866>0.05). 4 .The difference was not statistically significant between female and male(χ2=4.422, P=0.219>0.05). 5.χ2 test, The distributions of genotype in different level of hepatopathy with HCV infected was statistically significant(χ2=23.052, P=0.001<0.05).6. Analyze relation between HCV genotype and route of infection. The distributions of genotype had significant difference(χ2=60.270 , P=0.000<0.05). 7. Contrastively analyze ALT level and quantitation of HCV RNA in different genotypes, through one-factor analysis of variance, there was significant different of ALT levels in different genotypes(F=4.539, P=0.014<0.05).There was not significant different of quantitation of HCV RNA in different genotypes(F=2.059, P=0.135>0.05). Conclusions: The HCV genotypes found in Urumqi area are 1, 2, 3, and 6. HCV genotype 1 is the main genotype, and genotypes 2, 3, and 6 accounts for some proportions, that interpret the diversity of HCV genotype in Urumqi.
引文
[1] World Health Organization Initiative for Vaccine Research.Hepatitis C [OL]. (Accessed April 6, 2009, at http: //www.who.int/vaccine_research/ diseases/viral_cancers/en/index2.html)
[2] Sheppard CW, Finelli L & Alter, M. J. Global epidemiology of hepatitis C virus infection [J]. Lancet Infect Dis, 2005, 5, 558–567.
[3] Hepatology Unit, Theranostics R&D and Department of Medical Affairs, Innogenetics NV.Hepatitis B and C genotyping: methodologies and implications for patient management [J]. Journal of Gastroenterology and Hepatology, 2004, (19): 329-337.
[4] Fried MW, Shiffman ML, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection [J].N Engl J Med, 2002, 347: 975–982.
[5] Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J]. Lancet, 2001, 358: 958–965.
[6] Keam SJ, et al. Peginterferon-a-2a (40 KD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection [J]. Drugs, 2008, 68: 1273–1317.
[7] Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication [J]. Hepatology 2006, 43: S207–S220.
[8] Christophe Hézode, Nicole Forestier, et al. Telaprevir and Peginterferon with or without Rbavirin for Chronic HCV Infectio [J]. N Engl J Med, 2009, 360: 1839-1850.
[9] John G McHutchison, Gregory T verson, et al.Telaprevir with Peginterferon and Ribavirin or Chronic HCV Genotype 1 Infection [J].N Engl J Med, 2009; 360: 1827-1838.
[10]张瑞,杜绍财.丙型肝炎病毒基因分型的研究进展[J].中华检验医学杂志, 2006, 29(5): 469-471.
[11]中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华预防医学杂志, 2004, 38(3): 210-215.
[12] Simmonds P, Bukh J, Combet C, et al.Consensus Proposals for a unified System of nomenclature of hepatitis C virus genotypes [J]. Hepatology, 2005, 42: 962一973.
[13] Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA derived from a bloodborne non-A, non-B hepatitis genome [J]. Science, 1989, 244:359–362.
[14] Kuo G, Choo QL, Alter HJ, et al.An assay for circulating antibodies to a majoretiologic virus of human non-A, non-B hepatitis [J]. Science, 1989, 244:362–364.
[15] Di Bisceglie AM,Lyra AC,Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status [J]. Am J Gastroenterol, 2003, 98: 2060-2063.
[16] Organ Procurement and Transplantation Network. U.S. liver transplants performed: January 1, 1988-April 30, 2008 [OL]. (Accessed April 6,2009,at http ://www.Optn.org/.)
[17] Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence [J]. Adv Virus Res, 2004, 63: 71–180.
[18] Bartenschlager R, Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture [J]. Virus Res, 2007, 127: 195–207.
[19] Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update [J]. Int J Med Sci, 2006, 3: 29–34.
[20] Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus [J]. Hepatology, 2004, 39: 5–19.
[21] Branch AD, Stump DD, Gutierrez JA, et al. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others [J]. Semin Liver Dis, 2005, 25(1):105-117.
[22] Timothy LT, Matthew JE, Thomas von H, et al. Studying Hepatitis C Virus: Making the Best of a Bad Virus [J]. Virology, 2007, 81(17):8853-8867.
[23] Okamoto H, Kojima M. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability [J]. Virology, 1992, 190(2): 894-899.
[24] Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes [J]. Hepatology, 2005, 42: 962-973.
[25]张帆,王小红,王宇明,等.重庆地区HCV基因亚型的分布状态[J].第四军医大学学报, 2005, 26: 1253-1256.
[26] Lu L, Nakano T, He Y, et al. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants [J]. J Med Virol, 2005, 75: 538-549.
[27]吴永胜,白玉洁,杨春梅,等.乌鲁木齐地区丙型肝炎患者的病毒基因分型研究[J].临床内科杂志, 1997, 14(5): 265-266.
[28] Garten RJ, Lai S, Zhang J, et al.Rap id transmission of hepatitis C virus among young injecting heroin users in Southern China [J]. Int J Epidemiol, 2004, 33: 182-188.
[29] Zein NN, J Rakela, EL Krawitt, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy [J]. Ann Intern Med, 1996, 125:634–639.
[30] Berg T, U Hopf, K Stark, et al. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters [J]. J Hepatology, 1997, 26: 484–491.
[31] Pawlotsky JM, L Taskiris, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C [J]. J Infect Dis, 1995, 171: 1607–1610.
[32] Watson JP, AM Brind, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England [J]. Gut, 1996, 38:269–276.
[33]谢尧,赵辉,鸥蔚妮,等.不同感染途径慢性丙型肝炎患者HCV基因型分布的差异[J].中华实验和临床病毒学杂志, 2004, 18(3): 247–250.
[34] Hargiwara H, Mayashi N, Mita E, et al. Quantitation HCV RNA in serum of asymptomatic blood donors and patients with types C chronic liver disease [J]. Hepatology, 1993, 17(4): 545-550.
[35] Zhang FC, Cai XL, Huang JS, et al Study on the relationship of HCV-RNA between serum and liver tissue of hepatitis C [J]. Zhonghua Chuanranbing Zazhi (Chin J Infect Dis), 1999, 17(1): 15-17.
[36]张彦芳.丙型肝炎病毒感染的血清病毒定量研究[J].现代中西医结合杂志, 2002, 11(13): 1273-1274.
[37] Cui RH, bai ERH. The study of the relationship between the concentration of serum hepatitis C virus RNA and hepatocyte injury in patients with hepatitis C virus infection [J]. Hebei Medical Journal, 2001, 23(5): 328-329.
[38] Adinolfi LE, Utili R, Andreane A, et al. Serum HCV RNA levels correlate with histological liver damage and concurwith steatosis in progression of chronic hepatitis C [J]. Dig Dis Sci, 2001, 46(8): 1677-1683.
[39] Raghuraman S, Shaji RV, Sridharan G, et al. Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south Indi [J]. J Clin Virol, 2003, 26(1): 61-69.
[40] BlattL M, Mutchnich MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the united states [J]. J Viral Hepat, 2000, 7(3): 196-200.
[41]张复春,唐小平,蔡晓莉,等.丙型肝炎病毒基因型与血清HCVRNA含量关系及与干扰素应答的研究[J].中华微生物学和免疫学杂志, 1998, 18(2): 131-134.
[42]刘志英,魏红山,戴旺苏,等.北京地区丙型肝炎患者的丙型肝炎病毒基因分型[J].中华流行病学杂志, 2005, 26: 148-149.
[43] Silini E,Bono F, Cividini A, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities [J]. Hepatology, 1995, 21: 285-290.
[44]颜学兵,吴文漪,魏来,等.丙型肝炎病毒基因分型与临床关系的研究[J].江苏医药, 1999, 25(12): 912-913.
[45] Amoroso P, Rapicena M, Tosti ME, et a1.Correlation between virus genotype and chronicity rate in acute hepatitis c [J]. J Hepatol, 1998, 28(6): 939·944.
[46] Farci P, Purcell RH.Clinical significance of hepatitis C virus genotypes and quasispecies [J].Semin Liver Dis, 2000, 20: 103-126.
[47] Pozzato G, Kaneko S, Moreti M, et al.Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease [J]. J Med Virol, 1994, 43:291.
[48] Roffi L, Redaelli A, Colloredoq G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype [J]. Eur J Gastroenterol Hepatol, 2001, 13(5): 501-506.
[49] Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV [J]. J Clin Virol, 2001, 22(1): 11-29.
[50]许可,邓小昭,丁伟良,等.江苏省宜兴地区丙型肝炎病毒基因分型研究[J].中华流行病学杂志, 2005, 26: 901-903.
[51]王琳,徐东平,张玲霞.丙型肝炎病毒基因型分型及临床意义[J].肝脏, 2006, 12: 416-417.
[52] Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong [J]. Intervirology, 2006, 49: 96-98.
[1] Sarrazi NC.Diagnosis of hepatitis C:update 2004 [J]. Journal of Gastroenterology and Hepatology, 2004, 19:S88.
[2] Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B hepatitis genome [J].Science, 1989, 244:359.
[3] Simmonds P, Holmes EC, Cha TA, et al.Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region [J]. J Gen Virol, 1993, 74(Pt11): 2391-2399.
[4] Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on [J].J Gen Virol, 2004, 85:3173-3188.
[5] Farci P, Shimoda A, Coiana A, et al.The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies [J]. Science 2000, 288:339-344.
[6] Angela Dolganiuc, Serena Chang, Karen Kodys, el at.Hepatitis C Virus (HCV) Core Protein-Induced, Monocyte-Mediated Mechanisms of Reduced IFN-αand Plasmacytoid Dendritic Cell Loss in Chronic HCV Infection [J]. The Journal of Immunology, 2006, 177: 6758–6768.
[7] Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on [J].J Gen Virol, 2004, 85 : 3173-3188.
[8] Simmonds P, Bukh J, Combet C, et al.Consensus proposals for a unified systemof nomenclature of hepatitis C virus genotypes [J]. Hepatology, 2005, 42: 962-973.
[9] Luciano K. Silva, Raimundo Parana, et al. Hepatitis C virus genotypes in a northeastern area of Brazil [J]. Am J Trop Med Hyg, 2000, 62(2): 257–260.
[10]李莹,陈建杰.上海地区71例慢性丙型病毒性肝炎患者基因型分布研究[J].中西医结合肝病杂志, 2006, 16(6): 360-361.
[11] Franoi?se Bouchardeau, Jean Fran?ois Cantaloube, et al.Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV Assay [J]. Journal of Clinical Microbiology, 2007, 45(4):1140-1145.
[12]张翼冠,毛红菊,顾士民,等.基于膜显色结果判读的基因芯片快速检测丙型肝炎基因型方法的研究[J].中华肝脏病杂志, 2004, 12(5): 301-303.
[13]李宁,毛红菊,祁自柏,等.基因芯片法特异性检测丙型肝炎病毒的基因分型[J].中国免疫学杂志, 2005, 21(9): 687-689.
[14]王建春,袁玮,张秀岭,等.寡核苷酸阵列芯片检测丙型肝炎病毒的基因型及临床应用[J].中华检验医学杂志, 2005, 28(12): 1248-1252.
[15]孙亚臣,岳希全. RFLP法检测PBMCS和血浆中HCV基因型的相关性与慢性化的关系[J].中国实验诊断学, 2007, 11(2) : 205-207.
[16]邱国华,杜绍财,孙南雄,等.丙型肝炎病毒非编码区ABC程序酶切分型研究[J].中华肝脏病杂志, 2004, 12(4): 237-239
[17] Schroter M, Zollner B, Schafer P, et al. Genotyping of hepatitis C virus types 1, 2, 3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes [J]. J Clin Microbiol, 2002, 40: 2046-20504.
[18] Haverstick DM, Bullock GC, Bruns DE. Genotyping of hepatitis C virus by melting curve analysis: analytical characteristics and performance [J]. Clin Chem, 2004, 50: 2405-2407.
[19] Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR [J]. J Clin Virol, 2005, 34:108-114.
[20] Rolfe KJ, Alexander GJ, Wreghitt TG, et al.A real-time Taqman method for hepatitis C virus genotyping [J]. J Clin Virol, 2005, 34:115-121.
[21] Moghaddam A, Reinton N, Dalgard O.A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a [J]. J Viral Hepat, 2006, 13:222-229.
[22] Cook L, Sullivan K, Krantz EM, et al.Multiplex real-time reverse transcription-PCR assay for determination of hepatitis C virus genotypes [J]. J Clin Microbiol, 2006, 44: 4149-4156.
[23] Antonishyn NA, Ast VM, McDonald RR, et al.Rapid genotyping of hepatitis C virus by primer-specific extension analysis [J]. J Clin Microbiol, 2005, 43: 5158-5563.
[24] Lu L, Nakano T, He Y, et al. Hepatitis C virus genotype distribution in China: redominance of closely related subtype 1h isolates and existence of new genotype 6 variants [J]. J Med Virol, 2005, 75:538-549.
[25] Liew M, Erali M, Page S, et al.Hepatitis C genotyping by denaturing high-performance liquid chromatography [J]. J Clin Microbiol, 2004, 42:158-163.
[26] Stamenkovic G, Guduric J, Velickovic Z, et al. Analysis of 5' non-coding region in hepatitis C virus by single-strand conformation polymorphism and low-stringency single specific primer PCR [J]. Clin Chem Lab Med, 2001, 39: 948-952.
[27] Ilina EN, Malakhova MV, Generozov EV, et al. Matrix-assisted laser desorption ionization-time of flight (mass spectrometry) for hepatitis C virus genotyping [J]. J Clin Microbiol, 2005, 43: 2810-2815.
[28] Gui Tran.The role of hepatitis C virus in the pathogenesis of hepatocellular carcinoma[J]. Bioscience Horizons, 2008, 1(1):167-175.
[29] Zein NN.Clinical significance of hepatitis C virus genotypes [J]. Clin Microbiol Rev, 2000, 13: 223-235.
[30] Thomson BJ, Finch RG.Hepatitis C virus infection [J]. Clin Microbiol Infect, 2005, 11(2):86-94.
[31] Nousbaum JB, Pol S, Nalpas B, et al.Hepatitis C virus type Ib(II) infection in France and Italy.Collaborative Study Group [J]. Ann Intern Med, 1995, 122(3):161-168.
[32] Wong DA, Tong LK, Lim W.High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong [J]. Eur J Epidemiol, 1998, 14(5):421-426.
[33] Ling Lu, Chunhua Li, Yongshui Fu, et al. Complete genomes of hepatitis C virus (HCV) subtypes 6c, 6l, 6o, 6p and 6q: completion of a full panel of genomes for HCV genotype 6 [J].Journal of General Virology, 2007, 88: 1519–1525.
[34] Ling Lu, Chunhua Li, Yongshui Fu, et al. Complete genomes for hepatitis C virus subtypes 6f, 6i, 6j and 6m: viral genetic diversity among Thai blood donors and infected spouses [J]. Journal of General Virology, 2007, 88: 1505–1518.
[35] Zhou DX, Tang JW, Chu IM, et al.Hepatitis C virus genotype distribution among intravenous druguser and the general population in Hong Kong [J]. J Med Virol, 2006, 78(5):574-581.
[36] Neda Svirtlih, Dragan Delic, et al. Hepatitis C virus genotypes in Serbia and Montenegro: The prevalence and clinical significance [J]. World J Gastroenterol, 2007, 13(3):355-360.
[37] De Vries, et al. Genotype distribution amongst hepatitis C patients [J]. The Netherlands Journal of Medicine, 2006, 64(4): 109-113.
[38] Jean-Fran?oise Cantaloube, Pierre Gallian, et al.Genotype distribution and molecular epidemiology of Hepatitis C virus in blood donors from southeast France [J]. Journal of Clinical Microbiologic, 2005, 43(8): 3624-3629.
[39] Stella M. Martinez, Manuel B. Delgado, et al.High Rate of Infection with Hepatitis C Virus Genotype 4 in a District of Galicia, Spain [J]. J Clin Microbiol, 2005, 43(10):5403-5404.
[40] Rebecca J. Garten,Jinbing Zhang,Shenghan Lai,et al.Coinfection with HIV and Hepatitis C Virus among Injection Drug Users in Southern China [J]. Clinical Infectious Diseases, 2005, 41: S18–24.
[41]中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华预防医学杂志, 2004, 38(3): 210-215.
[42] Vicente Carren?o, Margarita Pardo, et al.Detection of Hepatitis C Virus (HCV) RNA in the Liver of Healthy, Anti-HCV Antibody–Positive, Serum HCV RNA–Negative Patients with Normal Alanine Aminotransferase Levels [J]. The Journal of Infectious Diseases, 2006, 194: 53–60.
[43]李颖,丁洋,等.慢性丙型肝炎患者血清HCV RNA, ALT与肝脏病理间的关系[J].世界华人消化杂志, 2006, 14(9): 916-919.
[44] John RT, Fayez M. Hamzeh, David L. Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis [J]. Journal of Clinical Microbiology, 2007, 45: 2426–2433.
[45] Silvia Franceschi, Maurizio Montella, et al.Hepatitis Viruses, Alcohol, and Tobacco in the Etiology of Hepatocellular Carcinoma in Italy [J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(4): 683-689.
[46] Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C [J]. Hepatology, 2003, 38:75-85.
[47] Jesper Brok, Lise L Gluud, Christian Gluud.Effects of Adding Ribavirin to Interferon to Treat Chronic Hepatitis C Infection [J]. Arch Intern Med, 2005, 165: 2206-2212.
[48] Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? [J]. J Hepatol, 2007, 47: 580-587.
[49] Pearlman BL, Ehleben C, Saifee S.Treatment Extension to 72 Weeks of Peginterferon and Ribavirin in Hepatitis C Genotype 1–Infected Slow Responders [J]. Hepatology, 2007, 46(6): 1688-1694.
[50] Shiffman ML, Suter F, Bacon BR,et al.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 [J]. N Engl J Med, 2007, 357: 124-134.
[51] Fried MW, Shiffman ML, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection [J]. N Engl J Med, 2002, 347: 975–982.
[52] Stephanos J, Hadziyannis, Hoel Sette Jr, et al. Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C [J]. Ann Intern Med, 2004, 140: 346-355.
[53]谢尧,徐道振,陆志檬,等. HCV基因型对慢性丙型肝炎干扰素疗效的影响[J].中华肝脏病杂志, 2004, 12:72-75.
[54] Kenneth KY, Marianne G, et al.Treatment responses in Asians and Caucasians with chronic hepatitis C infection [J]. World J Gastroenterol, 2008, 14(21): 3416-3420.
[55] Rebecca JG, Sheng HL, et al. Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China [J]. World J Gastroenterol, 2008, 14(12): 1878-1884.
[56] Brian LP.Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it [J]. World J Gastroenterol, 2008, 14(23): 3621-3627.
[57] Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong [J], Intervirology, 2006, 49: 96-98.
[58] Francesco G. De R, Olivia B, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C [J]. Journal of Antimicrobial Chemotherapy, 2006, 57: 360–363.
[59] Milton WT, Takuma T, et al. Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral Therapy [J]. J Virology, 2007, 81(7):3391-3401.
[2] Sheppard CW, Finelli L & Alter, M. J. Global epidemiology of hepatitis C virus infection [J]. Lancet Infect Dis, 2005, 5, 558–567.
[3] Hepatology Unit, Theranostics R&D and Department of Medical Affairs, Innogenetics NV.Hepatitis B and C genotyping: methodologies and implications for patient management [J]. Journal of Gastroenterology and Hepatology, 2004, (19): 329-337.
[4] Fried MW, Shiffman ML, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection [J].N Engl J Med, 2002, 347: 975–982.
[5] Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J]. Lancet, 2001, 358: 958–965.
[6] Keam SJ, et al. Peginterferon-a-2a (40 KD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection [J]. Drugs, 2008, 68: 1273–1317.
[7] Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication [J]. Hepatology 2006, 43: S207–S220.
[8] Christophe Hézode, Nicole Forestier, et al. Telaprevir and Peginterferon with or without Rbavirin for Chronic HCV Infectio [J]. N Engl J Med, 2009, 360: 1839-1850.
[9] John G McHutchison, Gregory T verson, et al.Telaprevir with Peginterferon and Ribavirin or Chronic HCV Genotype 1 Infection [J].N Engl J Med, 2009; 360: 1827-1838.
[10]张瑞,杜绍财.丙型肝炎病毒基因分型的研究进展[J].中华检验医学杂志, 2006, 29(5): 469-471.
[11]中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华预防医学杂志, 2004, 38(3): 210-215.
[12] Simmonds P, Bukh J, Combet C, et al.Consensus Proposals for a unified System of nomenclature of hepatitis C virus genotypes [J]. Hepatology, 2005, 42: 962一973.
[13] Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA derived from a bloodborne non-A, non-B hepatitis genome [J]. Science, 1989, 244:359–362.
[14] Kuo G, Choo QL, Alter HJ, et al.An assay for circulating antibodies to a majoretiologic virus of human non-A, non-B hepatitis [J]. Science, 1989, 244:362–364.
[15] Di Bisceglie AM,Lyra AC,Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status [J]. Am J Gastroenterol, 2003, 98: 2060-2063.
[16] Organ Procurement and Transplantation Network. U.S. liver transplants performed: January 1, 1988-April 30, 2008 [OL]. (Accessed April 6,2009,at http ://www.Optn.org/.)
[17] Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence [J]. Adv Virus Res, 2004, 63: 71–180.
[18] Bartenschlager R, Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture [J]. Virus Res, 2007, 127: 195–207.
[19] Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update [J]. Int J Med Sci, 2006, 3: 29–34.
[20] Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus [J]. Hepatology, 2004, 39: 5–19.
[21] Branch AD, Stump DD, Gutierrez JA, et al. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others [J]. Semin Liver Dis, 2005, 25(1):105-117.
[22] Timothy LT, Matthew JE, Thomas von H, et al. Studying Hepatitis C Virus: Making the Best of a Bad Virus [J]. Virology, 2007, 81(17):8853-8867.
[23] Okamoto H, Kojima M. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability [J]. Virology, 1992, 190(2): 894-899.
[24] Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes [J]. Hepatology, 2005, 42: 962-973.
[25]张帆,王小红,王宇明,等.重庆地区HCV基因亚型的分布状态[J].第四军医大学学报, 2005, 26: 1253-1256.
[26] Lu L, Nakano T, He Y, et al. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants [J]. J Med Virol, 2005, 75: 538-549.
[27]吴永胜,白玉洁,杨春梅,等.乌鲁木齐地区丙型肝炎患者的病毒基因分型研究[J].临床内科杂志, 1997, 14(5): 265-266.
[28] Garten RJ, Lai S, Zhang J, et al.Rap id transmission of hepatitis C virus among young injecting heroin users in Southern China [J]. Int J Epidemiol, 2004, 33: 182-188.
[29] Zein NN, J Rakela, EL Krawitt, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy [J]. Ann Intern Med, 1996, 125:634–639.
[30] Berg T, U Hopf, K Stark, et al. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters [J]. J Hepatology, 1997, 26: 484–491.
[31] Pawlotsky JM, L Taskiris, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C [J]. J Infect Dis, 1995, 171: 1607–1610.
[32] Watson JP, AM Brind, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England [J]. Gut, 1996, 38:269–276.
[33]谢尧,赵辉,鸥蔚妮,等.不同感染途径慢性丙型肝炎患者HCV基因型分布的差异[J].中华实验和临床病毒学杂志, 2004, 18(3): 247–250.
[34] Hargiwara H, Mayashi N, Mita E, et al. Quantitation HCV RNA in serum of asymptomatic blood donors and patients with types C chronic liver disease [J]. Hepatology, 1993, 17(4): 545-550.
[35] Zhang FC, Cai XL, Huang JS, et al Study on the relationship of HCV-RNA between serum and liver tissue of hepatitis C [J]. Zhonghua Chuanranbing Zazhi (Chin J Infect Dis), 1999, 17(1): 15-17.
[36]张彦芳.丙型肝炎病毒感染的血清病毒定量研究[J].现代中西医结合杂志, 2002, 11(13): 1273-1274.
[37] Cui RH, bai ERH. The study of the relationship between the concentration of serum hepatitis C virus RNA and hepatocyte injury in patients with hepatitis C virus infection [J]. Hebei Medical Journal, 2001, 23(5): 328-329.
[38] Adinolfi LE, Utili R, Andreane A, et al. Serum HCV RNA levels correlate with histological liver damage and concurwith steatosis in progression of chronic hepatitis C [J]. Dig Dis Sci, 2001, 46(8): 1677-1683.
[39] Raghuraman S, Shaji RV, Sridharan G, et al. Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south Indi [J]. J Clin Virol, 2003, 26(1): 61-69.
[40] BlattL M, Mutchnich MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the united states [J]. J Viral Hepat, 2000, 7(3): 196-200.
[41]张复春,唐小平,蔡晓莉,等.丙型肝炎病毒基因型与血清HCVRNA含量关系及与干扰素应答的研究[J].中华微生物学和免疫学杂志, 1998, 18(2): 131-134.
[42]刘志英,魏红山,戴旺苏,等.北京地区丙型肝炎患者的丙型肝炎病毒基因分型[J].中华流行病学杂志, 2005, 26: 148-149.
[43] Silini E,Bono F, Cividini A, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities [J]. Hepatology, 1995, 21: 285-290.
[44]颜学兵,吴文漪,魏来,等.丙型肝炎病毒基因分型与临床关系的研究[J].江苏医药, 1999, 25(12): 912-913.
[45] Amoroso P, Rapicena M, Tosti ME, et a1.Correlation between virus genotype and chronicity rate in acute hepatitis c [J]. J Hepatol, 1998, 28(6): 939·944.
[46] Farci P, Purcell RH.Clinical significance of hepatitis C virus genotypes and quasispecies [J].Semin Liver Dis, 2000, 20: 103-126.
[47] Pozzato G, Kaneko S, Moreti M, et al.Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease [J]. J Med Virol, 1994, 43:291.
[48] Roffi L, Redaelli A, Colloredoq G, et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype [J]. Eur J Gastroenterol Hepatol, 2001, 13(5): 501-506.
[49] Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV [J]. J Clin Virol, 2001, 22(1): 11-29.
[50]许可,邓小昭,丁伟良,等.江苏省宜兴地区丙型肝炎病毒基因分型研究[J].中华流行病学杂志, 2005, 26: 901-903.
[51]王琳,徐东平,张玲霞.丙型肝炎病毒基因型分型及临床意义[J].肝脏, 2006, 12: 416-417.
[52] Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong [J]. Intervirology, 2006, 49: 96-98.
[1] Sarrazi NC.Diagnosis of hepatitis C:update 2004 [J]. Journal of Gastroenterology and Hepatology, 2004, 19:S88.
[2] Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B hepatitis genome [J].Science, 1989, 244:359.
[3] Simmonds P, Holmes EC, Cha TA, et al.Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region [J]. J Gen Virol, 1993, 74(Pt11): 2391-2399.
[4] Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on [J].J Gen Virol, 2004, 85:3173-3188.
[5] Farci P, Shimoda A, Coiana A, et al.The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies [J]. Science 2000, 288:339-344.
[6] Angela Dolganiuc, Serena Chang, Karen Kodys, el at.Hepatitis C Virus (HCV) Core Protein-Induced, Monocyte-Mediated Mechanisms of Reduced IFN-αand Plasmacytoid Dendritic Cell Loss in Chronic HCV Infection [J]. The Journal of Immunology, 2006, 177: 6758–6768.
[7] Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on [J].J Gen Virol, 2004, 85 : 3173-3188.
[8] Simmonds P, Bukh J, Combet C, et al.Consensus proposals for a unified systemof nomenclature of hepatitis C virus genotypes [J]. Hepatology, 2005, 42: 962-973.
[9] Luciano K. Silva, Raimundo Parana, et al. Hepatitis C virus genotypes in a northeastern area of Brazil [J]. Am J Trop Med Hyg, 2000, 62(2): 257–260.
[10]李莹,陈建杰.上海地区71例慢性丙型病毒性肝炎患者基因型分布研究[J].中西医结合肝病杂志, 2006, 16(6): 360-361.
[11] Franoi?se Bouchardeau, Jean Fran?ois Cantaloube, et al.Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV Assay [J]. Journal of Clinical Microbiology, 2007, 45(4):1140-1145.
[12]张翼冠,毛红菊,顾士民,等.基于膜显色结果判读的基因芯片快速检测丙型肝炎基因型方法的研究[J].中华肝脏病杂志, 2004, 12(5): 301-303.
[13]李宁,毛红菊,祁自柏,等.基因芯片法特异性检测丙型肝炎病毒的基因分型[J].中国免疫学杂志, 2005, 21(9): 687-689.
[14]王建春,袁玮,张秀岭,等.寡核苷酸阵列芯片检测丙型肝炎病毒的基因型及临床应用[J].中华检验医学杂志, 2005, 28(12): 1248-1252.
[15]孙亚臣,岳希全. RFLP法检测PBMCS和血浆中HCV基因型的相关性与慢性化的关系[J].中国实验诊断学, 2007, 11(2) : 205-207.
[16]邱国华,杜绍财,孙南雄,等.丙型肝炎病毒非编码区ABC程序酶切分型研究[J].中华肝脏病杂志, 2004, 12(4): 237-239
[17] Schroter M, Zollner B, Schafer P, et al. Genotyping of hepatitis C virus types 1, 2, 3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes [J]. J Clin Microbiol, 2002, 40: 2046-20504.
[18] Haverstick DM, Bullock GC, Bruns DE. Genotyping of hepatitis C virus by melting curve analysis: analytical characteristics and performance [J]. Clin Chem, 2004, 50: 2405-2407.
[19] Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR [J]. J Clin Virol, 2005, 34:108-114.
[20] Rolfe KJ, Alexander GJ, Wreghitt TG, et al.A real-time Taqman method for hepatitis C virus genotyping [J]. J Clin Virol, 2005, 34:115-121.
[21] Moghaddam A, Reinton N, Dalgard O.A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a [J]. J Viral Hepat, 2006, 13:222-229.
[22] Cook L, Sullivan K, Krantz EM, et al.Multiplex real-time reverse transcription-PCR assay for determination of hepatitis C virus genotypes [J]. J Clin Microbiol, 2006, 44: 4149-4156.
[23] Antonishyn NA, Ast VM, McDonald RR, et al.Rapid genotyping of hepatitis C virus by primer-specific extension analysis [J]. J Clin Microbiol, 2005, 43: 5158-5563.
[24] Lu L, Nakano T, He Y, et al. Hepatitis C virus genotype distribution in China: redominance of closely related subtype 1h isolates and existence of new genotype 6 variants [J]. J Med Virol, 2005, 75:538-549.
[25] Liew M, Erali M, Page S, et al.Hepatitis C genotyping by denaturing high-performance liquid chromatography [J]. J Clin Microbiol, 2004, 42:158-163.
[26] Stamenkovic G, Guduric J, Velickovic Z, et al. Analysis of 5' non-coding region in hepatitis C virus by single-strand conformation polymorphism and low-stringency single specific primer PCR [J]. Clin Chem Lab Med, 2001, 39: 948-952.
[27] Ilina EN, Malakhova MV, Generozov EV, et al. Matrix-assisted laser desorption ionization-time of flight (mass spectrometry) for hepatitis C virus genotyping [J]. J Clin Microbiol, 2005, 43: 2810-2815.
[28] Gui Tran.The role of hepatitis C virus in the pathogenesis of hepatocellular carcinoma[J]. Bioscience Horizons, 2008, 1(1):167-175.
[29] Zein NN.Clinical significance of hepatitis C virus genotypes [J]. Clin Microbiol Rev, 2000, 13: 223-235.
[30] Thomson BJ, Finch RG.Hepatitis C virus infection [J]. Clin Microbiol Infect, 2005, 11(2):86-94.
[31] Nousbaum JB, Pol S, Nalpas B, et al.Hepatitis C virus type Ib(II) infection in France and Italy.Collaborative Study Group [J]. Ann Intern Med, 1995, 122(3):161-168.
[32] Wong DA, Tong LK, Lim W.High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong [J]. Eur J Epidemiol, 1998, 14(5):421-426.
[33] Ling Lu, Chunhua Li, Yongshui Fu, et al. Complete genomes of hepatitis C virus (HCV) subtypes 6c, 6l, 6o, 6p and 6q: completion of a full panel of genomes for HCV genotype 6 [J].Journal of General Virology, 2007, 88: 1519–1525.
[34] Ling Lu, Chunhua Li, Yongshui Fu, et al. Complete genomes for hepatitis C virus subtypes 6f, 6i, 6j and 6m: viral genetic diversity among Thai blood donors and infected spouses [J]. Journal of General Virology, 2007, 88: 1505–1518.
[35] Zhou DX, Tang JW, Chu IM, et al.Hepatitis C virus genotype distribution among intravenous druguser and the general population in Hong Kong [J]. J Med Virol, 2006, 78(5):574-581.
[36] Neda Svirtlih, Dragan Delic, et al. Hepatitis C virus genotypes in Serbia and Montenegro: The prevalence and clinical significance [J]. World J Gastroenterol, 2007, 13(3):355-360.
[37] De Vries, et al. Genotype distribution amongst hepatitis C patients [J]. The Netherlands Journal of Medicine, 2006, 64(4): 109-113.
[38] Jean-Fran?oise Cantaloube, Pierre Gallian, et al.Genotype distribution and molecular epidemiology of Hepatitis C virus in blood donors from southeast France [J]. Journal of Clinical Microbiologic, 2005, 43(8): 3624-3629.
[39] Stella M. Martinez, Manuel B. Delgado, et al.High Rate of Infection with Hepatitis C Virus Genotype 4 in a District of Galicia, Spain [J]. J Clin Microbiol, 2005, 43(10):5403-5404.
[40] Rebecca J. Garten,Jinbing Zhang,Shenghan Lai,et al.Coinfection with HIV and Hepatitis C Virus among Injection Drug Users in Southern China [J]. Clinical Infectious Diseases, 2005, 41: S18–24.
[41]中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华预防医学杂志, 2004, 38(3): 210-215.
[42] Vicente Carren?o, Margarita Pardo, et al.Detection of Hepatitis C Virus (HCV) RNA in the Liver of Healthy, Anti-HCV Antibody–Positive, Serum HCV RNA–Negative Patients with Normal Alanine Aminotransferase Levels [J]. The Journal of Infectious Diseases, 2006, 194: 53–60.
[43]李颖,丁洋,等.慢性丙型肝炎患者血清HCV RNA, ALT与肝脏病理间的关系[J].世界华人消化杂志, 2006, 14(9): 916-919.
[44] John RT, Fayez M. Hamzeh, David L. Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis [J]. Journal of Clinical Microbiology, 2007, 45: 2426–2433.
[45] Silvia Franceschi, Maurizio Montella, et al.Hepatitis Viruses, Alcohol, and Tobacco in the Etiology of Hepatocellular Carcinoma in Italy [J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(4): 683-689.
[46] Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C [J]. Hepatology, 2003, 38:75-85.
[47] Jesper Brok, Lise L Gluud, Christian Gluud.Effects of Adding Ribavirin to Interferon to Treat Chronic Hepatitis C Infection [J]. Arch Intern Med, 2005, 165: 2206-2212.
[48] Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? [J]. J Hepatol, 2007, 47: 580-587.
[49] Pearlman BL, Ehleben C, Saifee S.Treatment Extension to 72 Weeks of Peginterferon and Ribavirin in Hepatitis C Genotype 1–Infected Slow Responders [J]. Hepatology, 2007, 46(6): 1688-1694.
[50] Shiffman ML, Suter F, Bacon BR,et al.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 [J]. N Engl J Med, 2007, 357: 124-134.
[51] Fried MW, Shiffman ML, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection [J]. N Engl J Med, 2002, 347: 975–982.
[52] Stephanos J, Hadziyannis, Hoel Sette Jr, et al. Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C [J]. Ann Intern Med, 2004, 140: 346-355.
[53]谢尧,徐道振,陆志檬,等. HCV基因型对慢性丙型肝炎干扰素疗效的影响[J].中华肝脏病杂志, 2004, 12:72-75.
[54] Kenneth KY, Marianne G, et al.Treatment responses in Asians and Caucasians with chronic hepatitis C infection [J]. World J Gastroenterol, 2008, 14(21): 3416-3420.
[55] Rebecca JG, Sheng HL, et al. Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China [J]. World J Gastroenterol, 2008, 14(12): 1878-1884.
[56] Brian LP.Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it [J]. World J Gastroenterol, 2008, 14(23): 3621-3627.
[57] Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong [J], Intervirology, 2006, 49: 96-98.
[58] Francesco G. De R, Olivia B, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C [J]. Journal of Antimicrobial Chemotherapy, 2006, 57: 360–363.
[59] Milton WT, Takuma T, et al. Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral Therapy [J]. J Virology, 2007, 81(7):3391-3401.